Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Gemcitabin
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2007-03-12

Last Posted Date: 2022-06-13

Lead Sponsor: Spanish Lung Cancer Group

Target Recruit Count: 174

Registration Number: NCT00446225

Locations: 🇫🇷
Centre Hospitalier René Dubos, Cergy Pontoise, France
🇫🇷
Centre Hospitalier Du Mans, Le Mans, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 73 locations

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Terminated

Conditions: Esophageal Diseases
Esophageal Neoplasms

Interventions: Drug: Erlotinib
Drug: Avastin

First Posted Date: 2007-03-02

Last Posted Date: 2015-07-24

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT00442507

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Phase 3

Conditions: Pancreatic Cancer

Interventions: Drug: Capecitabine
Drug: Gemcitabine
Drug: Erlotinib

First Posted Date: 2007-02-26

Last Posted Date: 2012-07-09

Lead Sponsor: PD Dr. med. Volker Heinemann

Target Recruit Count: 280

Registration Number: NCT00440167

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2007-01-05

Last Posted Date: 2013-10-01

Lead Sponsor: Groupe Francais De Pneumo-Cancerologie

Target Recruit Count: 100

Registration Number: NCT00418704

Locations: 🇫🇷
Site 12, Aix En Provence, France
🇫🇷
Site 22, Beauvais, France
🇫🇷
Site 30, Charleville Mezieres, France

and more 19 locations

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Phase 3

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Placebo
Drug: Erlotinib
Other: Standard of care

First Posted Date: 2006-12-18

Last Posted Date: 2016-11-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 94

Registration Number: NCT00412217

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Bexarotene
Drug: Erlotinib

First Posted Date: 2006-12-14

Last Posted Date: 2020-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00411632

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2006-12-12

Last Posted Date: 2017-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT00410059

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cetuximab
Drug: erlotinib

First Posted Date: 2006-12-07

Last Posted Date: 2017-05-08

Lead Sponsor: University of California, Davis

Target Recruit Count: 64

Registration Number: NCT00408499

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Parotid Gland Cancer
Head and Neck Cancer
Thyroid Gland Cancer
Melanoma
Stage IV Head and Neck Cancer

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Bevacizumab
Drug: Erlotinib
Radiation: Radiotherapy

First Posted Date: 2006-11-30

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT00405405

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3

Completed

Conditions: Oral Cancer

Interventions: Drug: Placebo
Drug: Erlotinib

First Posted Date: 2006-11-22

Last Posted Date: 2020-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 303

Registration Number: NCT00402779

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
The Univeristy of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy